Purpose: The aim of our study was to evaluate the association between low-density lipoprotein cholesterol (LDL-C) level, statin treatment and the incidence of new antihypertensive treatment in a large population sample. Methods: A population-based cohort of 23,849 subjects from two Italian Local Health Units (LHU) aged 18 years or older with at least one LDL-C measurement and free of antihypertensive treatment at baseline was followed from the LDL-C date until death or December 31, 2009. The cohort was subdivided into two groups (LDL-C Results: During the mean follow-up of 1.3 years, 10.4% (n=1,382) of patients with LDL-C < target and 13.6% (n=1,442) of patients with LDL-C ≥ target started antihypertensive treatment. Compared with the LDL-C < target group, the LDL-C ≥ target group showed a higher overall incidence rate (7.59 vs 10.78 per 100 person-years, P<0.001). In the multivariable Cox regression analysis, after adjustments for the potential confounding variables, compared with LDL-C ≥ target group, the hazard ratio (HR) of AHT treatment was reduced among those with LDL-C < target (HR=0.91; 95%CI: 0.84-0.98). Significant HRs were also observed for age – increasing age increases the risk of new cases of AHT treatment than the age group below 45 years –, diabetes (HR=1.32; 95%CI: 1.16-1.49) and previous CV disease (HR=0.35; 95%CI: 0.20-0.63). Gender, CV diseases and statin treatment per se were not found significant predictors of the incidence of antihypertensive treatment. Conclusion: A better control of serum cholesterol levels seems to be associated to a significantly lower incidence of new antihypertensive treatment in a large cohort of general population.
Cicero A.F.G., Degli Esposti L., Saragoni S., Buda S., Radici S., Lilli P., et al. (2012). Cholesterol control and incident antihypertensive treatment in hypercholesterolemic subjects treated or not with statins: a pharmacoepidemiological report. EUROPEAN HEART JOURNAL, 33(Suppl 1), 775-775.
Cholesterol control and incident antihypertensive treatment in hypercholesterolemic subjects treated or not with statins: a pharmacoepidemiological report
CICERO, ARRIGO FRANCESCO GIUSEPPE;BORGHI, CLAUDIO
2012
Abstract
Purpose: The aim of our study was to evaluate the association between low-density lipoprotein cholesterol (LDL-C) level, statin treatment and the incidence of new antihypertensive treatment in a large population sample. Methods: A population-based cohort of 23,849 subjects from two Italian Local Health Units (LHU) aged 18 years or older with at least one LDL-C measurement and free of antihypertensive treatment at baseline was followed from the LDL-C date until death or December 31, 2009. The cohort was subdivided into two groups (LDL-C Results: During the mean follow-up of 1.3 years, 10.4% (n=1,382) of patients with LDL-C < target and 13.6% (n=1,442) of patients with LDL-C ≥ target started antihypertensive treatment. Compared with the LDL-C < target group, the LDL-C ≥ target group showed a higher overall incidence rate (7.59 vs 10.78 per 100 person-years, P<0.001). In the multivariable Cox regression analysis, after adjustments for the potential confounding variables, compared with LDL-C ≥ target group, the hazard ratio (HR) of AHT treatment was reduced among those with LDL-C < target (HR=0.91; 95%CI: 0.84-0.98). Significant HRs were also observed for age – increasing age increases the risk of new cases of AHT treatment than the age group below 45 years –, diabetes (HR=1.32; 95%CI: 1.16-1.49) and previous CV disease (HR=0.35; 95%CI: 0.20-0.63). Gender, CV diseases and statin treatment per se were not found significant predictors of the incidence of antihypertensive treatment. Conclusion: A better control of serum cholesterol levels seems to be associated to a significantly lower incidence of new antihypertensive treatment in a large cohort of general population.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
